Physician profile
Hedieh Davanloo
NPI 1659567758
$2,949.41
in general payments reported to CMS, 2019-2025
12 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2021: $146 · 2022: $316 · 2023: $672 · 2024: $495 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,444.94 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $500.01 | 2021-2025 | |
| Abbvie INC. | $325.93 | 2019 | |
| Celgene Corporation | $232.08 | 2019 | |
| Lilly USA, LLC | $216.33 | 2019-2025 | Kisunla, Mounjaro |
| Amgen INC. | $83.81 | 2019 | |
| Exact Sciences Corporation | $53.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $25.00 | 2019 | |
| Promius Pharma LLC | $22.91 | 2019 | |
| Mylan Specialty L.P. | $21.29 | 2019 | |
| Astellas Pharma US INC | $12.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hedieh Davanloo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.